What Is Tirzepatide?

1. What Is Tirzepatide?

Tirzepatide is the active ingredient in Mounjaro and Zepbound. The current DailyMed Mounjaro label and DailyMed Zepbound label describe it as a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist.

Tirzepatide is not itself “Mounjaro” or “Zepbound.” It is the molecule inside those branded prescription products. The brand name indicates the specific product label, the molecule name identifies the active ingredient, and the receptor language describes how the drug is classified.

Public shorthand often collapses these facts, using “tirzepatide,” “Mounjaro,” “Zepbound,” “GLP-1,” “weight-loss shot,” or “diabetes drug” interchangeably, even though they have distinct meanings.

2. Why Is Tirzepatide Called Dual GIP/GLP-1?

Tirzepatide is called dual GIP/GLP-1 because the current Mounjaro and Zepbound labels state that tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors. This makes “dual GIP and GLP-1 receptor agonist” more precise than classifying it only as a GLP-1 medication.

GLP-1 is a familiar public term because medications such as semaglutide made “GLP-1” part of everyday health news. GIP is another incretin-related hormone pathway. Tirzepatide is frequently grouped into GLP-1 conversations because it includes GLP-1 receptor activity, but its label language includes both receptors.

A broad phrase like “GLP-1 drugs” hides differences between molecules. For example, semaglutide and tirzepatide are not the same active ingredient. For broader background, see What Is a GLP-1?.

3. How Is Tirzepatide Related to Mounjaro?

Mounjaro is a brand name for tirzepatide. The current DailyMed Mounjaro label states Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.

FDA’s Drug Trials Snapshot for Mounjaro notes the agency approved Mounjaro based on evidence from nine clinical trials of 7,769 patients with type 2 diabetes mellitus, anchoring Mounjaro in its original type 2 diabetes approval context.

In short, Mounjaro contains tirzepatide and is labeled for type 2 diabetes glycemic control.

For a brand-specific explainer, see What Is Mounjaro?. For tracking, see the Mounjaro Tracker App.

4. How Is Tirzepatide Related to Zepbound?

Zepbound is also a brand name for tirzepatide. The current DailyMed Zepbound label lists two U.S. indications: reducing excess body weight and maintaining weight reduction long term in adults with obesity or certain adults with overweight, and treating moderate to severe obstructive sleep apnea in adults with obesity.

FDA’s November 2023 chronic weight-management approval announcement stated that tirzepatide, Zepbound’s active ingredient, was already approved under the trade name Mounjaro for adults with type 2 diabetes. FDA’s December 2024 OSA approval announcement later described Zepbound as approved for moderate to severe obstructive sleep apnea in adults with obesity, used with a reduced-calorie diet and increased physical activity.

While Mounjaro and Zepbound both contain the active ingredient tirzepatide, their labeled populations and indications are not identical.

For the brand-specific page, see What Is Zepbound?. For tracking, see the Zepbound Tracker App or Tirzepatide Tracker App.

5. Molecule, Brand, and Label Are Separate Facts

Understanding tirzepatide involves three distinct layers: the molecule, the brand, and the label. The molecule is tirzepatide. The U.S. brand may be Mounjaro or Zepbound. The label context depends on which brand and which current prescribing information you are reading.

Separating these layers helps clarify that “Mounjaro” and “Zepbound” are not interchangeable terms, and that “GLP-1” alone does not fully describe the drug’s mechanism of action.

6. Why the Distinction Matters

Because labels change and brand names carry specific regulatory contexts, relying on current prescribing information is more accurate than public shorthand. DailyMed shows recent label updates for both Mounjaro and Zepbound, keeping the distinction between the products clear.

Clear personal or medical records separate these details:

• Active ingredient: tirzepatide
• Brand name: Mounjaro or Zepbound
• Label context: type 2 diabetes, chronic weight management, or OSA
• Source checked: current label, FDA announcement, or another high-quality source

This precision is useful for reading health news, organizing personal records, and understanding prescription labels.

7. What Is Tirzepatide FAQ

• What is tirzepatide in simple terms?

  Tirzepatide is an active ingredient used in prescription medicines including Mounjaro and Zepbound. Current U.S. labels describe it as a GIP receptor and GLP-1 receptor agonist, which is why it is often discussed with GLP-1 medications.

• Is tirzepatide the same as Mounjaro or Zepbound?

  No. Tirzepatide is the active ingredient. Mounjaro and Zepbound are brand names with different U.S. label contexts. Mounjaro is labeled for type 2 diabetes glycemic control, while Zepbound is labeled for chronic weight management and certain OSA use.

• Why is tirzepatide called a dual GIP/GLP-1 receptor agonist?

  The Mounjaro and Zepbound labels state that tirzepatide selectively binds to and activates both GIP and GLP-1 receptors. That receptor wording is more precise than calling tirzepatide only a GLP-1 drug.

• Is tirzepatide approved for diabetes, weight management, or OSA?

  The answer depends on the brand label. Mounjaro is the tirzepatide brand labeled for type 2 diabetes glycemic control. Zepbound is the tirzepatide brand labeled for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity.

8. Sources